InvestSMART

Argenica Therapeutics Limited (ASX: AGN) - Announcements

Current share price for AGN : $0.140 0.015 (12%)+

ASX company news and announcements for Argenica Therapeutics Limited (AGN) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Argenica Therapeutics Limited (AGN) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Argenica Therapeutics Limited (AGN), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Argenica Therapeutics Limited (AGN)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$18 Positive Preclinical Data for ARG-007 Neuroprotection in HIE 3 Nov 2021 8:14AM $0.380 $0.140 fallen by 63.16%
$18 Quarterly Activities/Appendix 4C Cash Flow Report 28 Oct 2021 8:11AM $0.360 $0.140 fallen by 61.11%
$18 Investor Presentation 27 Oct 2021 8:17AM $0.360 $0.140 fallen by 61.11%
$18 Phase 1 Clinical Trial Overview & Roadmap 18 Oct 2021 9:10AM $0.400 $0.140 fallen by 65%
$18 Notice of Annual General Meeting/Proxy Form 15 Oct 2021 11:08AM $0.405 $0.140 fallen by 65.43%
$18 Application for quotation of securities - AGN 14 Oct 2021 12:31PM $0.405 $0.140 fallen by 65.43%
$18 Release of Restricted Securities from Escrow 4 Oct 2021 8:15AM $0.370 $0.140 fallen by 62.16%
$18 Argenica Partners With Linear For Phase 1 Clinical Trial 30 Sep 2021 9:52AM $0.375 $0.140 fallen by 62.67%
$18 Date of AGM & Closing Date for Director Nominations 21 Sep 2021 5:15PM $0.395 $0.140 fallen by 64.56%
$18 Argenica Achieves Manufacturing Milestones 14 Sep 2021 9:06AM $0.340 $0.140 fallen by 58.82%
$18 Appendix 4G & Corporate Governance Statement 27 Aug 2021 9:38AM $0.260 $0.140 fallen by 46.15%
$18 Appendix 4E & Annual Report 30 June 2021 27 Aug 2021 8:04AM $0.260 $0.140 fallen by 46.15%
$18 Appendix 3G 11 Aug 2021 5:14PM $0.200 $0.140 fallen by 30%
$18 Proposed issue of securities - AGN 5 Aug 2021 12:02PM $0.195 $0.140 fallen by 28.21%
$18 Issue of Options 5 Aug 2021 11:57AM $0.195 $0.140 fallen by 28.21%
$18 Quarterly Activities/Appendix 4C Cash Flow Report 29 Jul 2021 8:10AM $0.210 $0.140 fallen by 33.33%
$18 Grant Secured to Advance Pre-Clinical Studies Of ARG-007 21 Jul 2021 9:21AM $0.195 $0.140 fallen by 28.21%
$18 Study Additional Information 13 Jul 2021 10:38AM $0.225 $0.140 fallen by 37.78%
$18 Study Shows ARG-007 Does Not Degrade 12 Jul 2021 9:45AM $0.215 $0.140 fallen by 34.88%
$18 Argenica Completes Pilot Pre-Clinical Pharmacokinetics Study 1 Jul 2021 9:46AM $0.200 $0.140 fallen by 30%
$18 Change of Registered Office 30 Jun 2021 5:28PM $0.200 $0.140 fallen by 30%
$18 Investor Presentation 16 Jun 2021 8:42AM $0.215 $0.140 fallen by 34.88%
$18 Argenica Commences Trading on ASX 11 Jun 2021 10:35AM n/a $0.140 n/a
$18 Becoming a substantial holder 9 Jun 2021 6:25PM n/a $0.140 n/a
$18 Becoming a substantial holder 9 Jun 2021 6:13PM n/a $0.140 n/a

251 - 275 of 288 results

Page 11 of 12

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.